Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

OSTX

OS Therapies Inc

Sep 20 • 03:33PM ET

3.55

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • AMEX

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	21.76%	Shs Outstand	20.05M	Perf Week	3.20%
Market Cap	71.18M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	15.69M	Perf Month	-12.13%
Income	-	PEG	-	EPS next Q	-0.12	Inst Own	-	Short Float	0.16%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.09	Perf Half Y	-
Book/sh	-4.52	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.02M	Perf Year	-
Cash/sh	0.00	P/C	790.86	EPS next 5Y	-	ROE	-	52W Range	2.51 - 4.90	Perf YTD	41.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-27.55%	Beta	-
Dividend TTM	-	Quick Ratio	0.01	Sales past 5Y	-	Gross Margin	-	52W Low	41.43%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	0.01	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	51.22	Volatility	8.80% 10.40%
Employees	-	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	15.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-370.16%	Payout	-	Rel Volume	0.31	Prev Close	3.55
Sales Surprise	-	EPS Surprise	-134.62%	Sales Q/Q	-	Earnings	Aug 28	Avg Volume	273.92K	Price	3.55
SMA20	-7.10%	SMA50	-3.50%	SMA200	-3.50%	Trades		Volume	79,889	Change	0.00%

Sep-13-24 08:09AM	OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates (Business Wire)
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-11-24 08:15AM	OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models (ACCESSWIRE) -6.40%
Sep-05-24 08:22AM	OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference (Business Wire)
Aug-29-24 07:53AM	OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose (Business Wire)
08:00AM	Loading…
Aug-22-24 08:00AM	OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board (Business Wire)
06:00AM	OS Therapies Clarifies CUSIP of Common Stock (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-19-24 08:30AM	OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS (Business Wire) +14.66%
Aug-15-24 08:30AM	OS Therapies Reports Second Quarter 2024 Financial Results (ACCESSWIRE) +12.03%
Aug-09-24 09:00AM	OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE) +33.78%
Aug-06-24 08:35AM	OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board (ACCESSWIRE) +17.37%
Aug-02-24 08:55AM	OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board (Business Wire) +59.36%
Jul-31-24 06:21PM	OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX" (Business Wire)
Jul-24-24 10:48AM	OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer (Business Wire)
12:44PM	Loading…
Jun-03-24 12:44PM	OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma (Business Wire)

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OSTX

OS Therapies Inc

Upgrade your FINVIZ experience